Publications in collaboration with researchers from Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (23)

2023

  1. Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning

    Genome Medicine, Vol. 15, Núm. 1

  2. Prevalence of treated patients with Alzheimer’s disease: current trends and COVID-19 impact

    Alzheimer's Research and Therapy, Vol. 15, Núm. 1

2022

  1. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

    JAMA Neurology, Vol. 79, Núm. 3, pp. 228-243

2021

  1. Accelerated long-term forgetting in individuals with subjective cognitive decline and amyloid-β positivity

    International Journal of Geriatric Psychiatry, Vol. 36, Núm. 7, pp. 1037-1049

  2. Long runs of homozygosity are associated with Alzheimer’s disease

    Translational Psychiatry, Vol. 11, Núm. 1

2019

  1. Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer’s disease cerebrospinal fluid*

    Molecular and Cellular Proteomics, Vol. 18, Núm. 3, pp. 546-560

  2. Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid-β positivity

    Cortex, Vol. 121, pp. 117-124

  3. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project

    Alzheimer's and Dementia, Vol. 15, Núm. 10, pp. 1333-1347

  4. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

    Alzheimer's and Dementia, Vol. 15, Núm. 6, pp. 742-753

  5. Neuronal p38α mediates age-associated neural stem cell exhaustion and cognitive decline

    Aging Cell, Vol. 18, Núm. 6

  6. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: A cross-sectional analysis from the AB255 Study

    Alzheimer's Research and Therapy, Vol. 11, Núm. 1

  7. Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels

    Journal of Alzheimer's Disease, Vol. 70, Núm. 1, pp. 211-225

2018

  1. Cortical microstructural changes along the Alzheimer's disease continuum

    Alzheimer's and Dementia, Vol. 14, Núm. 3, pp. 340-351

2017

  1. Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum

    Neurobiology of Aging, Vol. 53, pp. 192.e1-192.e4

  2. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study

    Movement Disorders, Vol. 32, Núm. 7, pp. 1066-1073

2016

  1. Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study

    Alzheimer's and Dementia, Vol. 12, Núm. 2, pp. 154-163

2015

  1. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease

    Neurology, Vol. 85, Núm. 7, pp. 626-633

2014

  1. Diet, cognition, and Alzheimer's disease: Food for thought

    European Journal of Nutrition, Vol. 53, Núm. 1, pp. 1-23

  2. Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer's disease: A multicenter study in Spain

    Journal of Alzheimer's Disease, Vol. 39, Núm. 4, pp. 719-726

2012

  1. The impact of silent vascular brain burden in cognitive impairment in Parkinson's disease

    European Journal of Neurology, Vol. 19, Núm. 8, pp. 1100-1107